Skip to main content
. Author manuscript; available in PMC: 2021 Jun 14.
Published in final edited form as: N Engl J Med. 2019 May 2;380(18):1726–1737. doi: 10.1056/NEJMoa1817226

Figure 1. Response to bb2121 Infusion.

Figure 1.

Shown are the best responses among individual patients according to dose (50×106 to 800×106) of chimeric antigen receptor–positive (CAR+) T cells. All responses were confirmed and assessed according to the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma (details on the criteria for disease response are provided in the Supplementary Appendix). Asterisks indicate patients with a high tumor burden (≥50% bone marrow plasma cells). MRD denotes minimal residual disease.